Announcement on Change of "Drug Manufacturing License"
Filed with SSE · · 3 pages · Chinese
Summary by 6ix AI
Henan Taloph Pharmaceutical Stock Co. Ltd. announced a change in its "Drug Manufacturing License." The company received a renewed license from the Henan Provincial Drug Administration, which includes changes to its production scope and lines. The new license is valid until the end of a specified year and outlines the company's production capabilities. The announcement also includes a risk warning regarding potential impacts from industry regulations and market changes.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Henan Taloph Pharmaceutical Stock Co. Ltd. on 6ix
Earlier from Henan Taloph Pharmaceutical Stock
- Announcement on Implementation of Dividend Distribution for Q1-Q3 2025
- Announcement on Using Idle Self-owned Funds for Entrusted Wealth Management
- Plan for Issuing A-shares to Specific Objects in 2025
- Announcement on Continued Stock Suspension Due to Controlling Shareholder's Planning of Major Matters
- Announcement on Stock Suspension Due to Controlling Shareholder's Planning of Major Matters
Later from Henan Taloph Pharmaceutical Stock
- Announcement on Progress in Providing Guarantee for Financing of Subordinated Holding Subsidiary
- Announcement on Adjusting Guarantee Amount among Subsidiaries and Providing Guarantee for Subsidiaries
- Announcement on Progress in Receiving the "Decision on No Further Review of the Anti-Monopoly Examination for Concentration of Undertakings" and Proposed Change of Controlling Shareholder and Actual Controller
- Announcement on Results of Issuing Phase I Ultra-Short-Term Financing Bonds of 2026
- Announcement on Completion of Redemption of the Phase I Ultra-short-term Financing Bonds for 2025
Follow Henan Taloph Pharmaceutical Stock into a list and get an email when it puts out news.
Follow Henan Taloph Pharmaceutical Stock